Compounds / Cognitive / Noopept

Noopept

Noopept (GVS-111 — Dipeptide Neuroprotective Agent)

CognitiveFDA: Not approved (registered in Russia)

Overview

Registered Russian drug for cognitive impairment. Well-studied neuroprotective effects. Often compared to Piracetam but far more potent (~1000×) at much lower doses.

Mechanism of Action

Synthetic dipeptide (cycloprolylglycine prodrug). Increases BDNF and NGF expression. Modulates AMPA and NMDA receptors. Neuroprotective. Anxiolytic properties. Registered drug in Russia.

Molecular Profile

Molecular weight

318.4 Da

Key Research Findings

BDNF/NGF upregulation; AMPA/NMDA modulation; neuroprotection; registered Russian drug; 1000× more potent than piracetam.

Published Research

Bull Exp Biol Med (2008)

Ostrovskaya RU et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus

View source

Related Cognitive Compounds

Semax NA Semax Amidate Selank Adalank Adamax Dihexa

Clinical Guidance

Research data is not a treatment plan. If you are considering Noopept, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running Noopept? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals